Novabay Pharmaceuticals Inc (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 0 | 0 | 10,455 | 14,404 | 10,204 |
| Cost of Goods | N/A | N/A | 4,371 | 6,623 | 3,689 |
| Gross Profit | N/A | N/A | 6,084 | 7,781 | 6,515 |
| Operating Expenses | 8,439 | 7,379 | 10,557 | 22,821 | 16,066 |
| Operating Income | -8,439 | -7,379 | -4,102 | -14,417 | -8,862 |
| Other Income | -24,783 | -1,371 | -2,043 | 3,809 | 3,038 |
| Pre-tax Income | -33,222 | -8,750 | -6,145 | -10,608 | -5,824 |
| Net Income Continuous | -33,222 | -8,750 | -6,145 | -10,608 | -5,824 |
| Net Income Discontinuous | 11,081 | 1,527 | -3,495 | N/A | N/A |
| Net Income | $-22,141 | $-7,223 | $-9,640 | $-10,608 | $-5,824 |
| EPS Basic Total Ops | -3.80 | -12.68 | -695.70 | -1,765.73 | -919.58 |
| EPS Basic Continuous Ops | -5.70 | -14.93 | -550.10 | -1,151.89 | -816.51 |
| EPS Basic Discontinuous Ops | 1.90 | 2.25 | -145.60 | N/A | N/A |
| EPS Diluted Total Ops | -3.80 | -12.68 | -695.70 | -1,765.73 | -919.58 |
| EPS Diluted Continuous Ops | -5.70 | -14.93 | -550.10 | -1,151.89 | -816.51 |
| EPS Diluted Discontinuous Ops | 1.90 | 2.25 | -145.60 | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | N/A | -12.65 | -585.67 | -1,765.74 | -916.92 |
| EBITDA(a) | $-8,191 | $-6,506 | $-4,051 | $-7,197 | $-8,743 |